FDA To Companion Dx Developers: Pre-Trial Assay Validation Is Key
This article was originally published in The Pink Sheet Daily
The assay is used to select the target population enrolled in the trial, and the safety and efficacy of the drug are determined based on this population, CDRH's Roscoe emphasized to an assemblage of biomedical researchers, entrepreneurs and other stakeholders.
You may also be interested in...
FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.